Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non-adjuvanted Trivalent Influenza Vaccine Fluzone in Children 6 to < 72 Months of Age

NCT01346592 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01346592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01346592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non-adjuvanted Trivalent Influenza Vaccine Fluzone in Children 6 to < 72 Months of Age
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2011
Completion date
July 31, 2012
Enrollment
6,104 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

influenza disease